A phase 3 clinical trial reveals semaglutide, the active ingredient in Ozempic and Wegovy, effectively treats Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious fatty liver disease. Over 62% of patients receiving weekly semaglutide showed improvement, compared to 34% in the placebo group. The drug also reduced liver fibrosis. Researchers highlight semaglutide's potential as a new treatment option for MASH, given its impact on both liver health and underlying metabolic issues. The study, published in the New England Journal of Medicine, is ongoing.

Prepared by Olivia Bennett and reviewed by editorial team.